2018
DOI: 10.1093/fampra/cmx134
|View full text |Cite
|
Sign up to set email alerts
|

International definition of a point-of-care test in family practice: a modified e-Delphi procedure

Abstract: The definition emerging from this study can inform family practitioners, laboratory specialists, policymakers and manufacturers on the most widely supported and recognized definition and could act as a clear starting point for the organization and execution of professional point-of-care testing in family practice worldwide.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
29
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 30 publications
(30 citation statements)
references
References 9 publications
0
29
0
1
Order By: Relevance
“…For example the AQT90 FLEX immunoassay analyser can perform six tests (D‐dimer, Procalcitonin, CRP, NT‐proBNP, Troponin T and Troponin I), yet only one evaluation, in this case of its D‐Dimer test, was identified in the review. However, since this instrument requires a large volume of blood, and therefore a venipuncture instead of a fingerpick, it may not be considered as a POCT . Therefore, studies investigating this multiple‐test device (or similar devices) without using POCT terminology may have been missed.…”
Section: Discussionmentioning
confidence: 99%
“…For example the AQT90 FLEX immunoassay analyser can perform six tests (D‐dimer, Procalcitonin, CRP, NT‐proBNP, Troponin T and Troponin I), yet only one evaluation, in this case of its D‐Dimer test, was identified in the review. However, since this instrument requires a large volume of blood, and therefore a venipuncture instead of a fingerpick, it may not be considered as a POCT . Therefore, studies investigating this multiple‐test device (or similar devices) without using POCT terminology may have been missed.…”
Section: Discussionmentioning
confidence: 99%
“…At enrolment, a nurse with experience in sexual health collected two vaginal swabs for POC testing on the Xpert CT/NG and the OSOM TV assays, and one Eswab (Copan, Brescia, Italy) specimen, which was sent to the regional National Health Laboratory Services reference laboratory for DNA extraction and parallel testing on the Anyplex II STI-7 Detection assay (Seegene, Seoul, Korea) within 24 hours of sample collection, according to Clinical and Laboratory Standards Institute requirements. Considering that all participants received their results during the same visit and the tests were performed in the clinic, we used the term ‘point-of-care’ for both assays, in line with the following consensus definition: ‘a point-of-care test…is a test to support clinical decision making, which is performed by a qualified…staff nearby the patient…during or very close to the time of consultation, to help the patient and physician to decide upon the best suited approach, and of which the results should be known at the time of the clinical decision making’ 15. All POC tests were processed according to manufacturers’ specification (www.sekisuidiagnostics.com/products/130-osom-trichomonas-test and www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/sexual-health/xpert-ct-ng) by laboratory technologists with experience using the GeneXpert platform at the clinic laboratory, but no access to participant clinical data.…”
Section: Methodsmentioning
confidence: 99%
“…POC tests for SARS-CoV-2 can help provide real-time and on-site detection of SARS-CoV-2 infection without the need for specialised laboratory equipment (12,13). Primary care physicians (PCPs) can increase the volume of face-to-face clinical encounters and use POC tests during (or very close to) the time of consultation to detect and prevent contagion within the clinic (14). Additionally, POC tests can act as a safety measures to control and contain risk in view of the uncertainties concerning the real-world e cacy of different vaccines (15), new variants of concern (16,17), complexities of vaccine hesitancy (18,19).…”
Section: Introductionmentioning
confidence: 99%